公开(公告)号：US20090143275A1

公开(公告)日：2009-06-04

申请号：US12169983

申请日：2008-07-09

申请人： Michael J. Pugia ,  Rui Ma

发明人： Michael J. Pugia ,  Rui Ma

IPC分类号： A61K38/02 ,  A61P3/10 ,  A61P35/00

CPC分类号： C07K14/72 ,  A61K38/00

摘要： Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.

摘要翻译： 公开了使用脂联素受体R1的C末端片段治疗糖尿病，异常脂肪细胞活性和胰岛素抵抗的方法。 还公开了使用脂联素受体R1的C末端片段在健康和糖尿病患者中分泌胰岛素的方法。 此外，公开了使用脂联素受体R1的C末端片段增加健康患者的胰岛素水平的方法。 另外，处理异常脂肪细胞活性，治疗代谢综合征，引起胰岛素分泌，增加胰岛素水平，抑制胰岛素降解酶，治疗阿尔茨海默氏病，治疗与脂联素水平相关的心血管疾病，抑制ADAM-17酶，治疗与 公开了TNF-α和治疗与HER2-neu相关的病症。 还公开了组合物，剂型和试剂盒。

公开(公告)号：US08865648B2

公开(公告)日：2014-10-21

申请号：US13265968

申请日：2010-04-13

申请人： Michael J. Pugia ,  Rui Ma

发明人： Michael J. Pugia ,  Rui Ma

IPC分类号： A61K38/00 ,  A61K38/26 ,  A61K38/22 ,  C07K14/605 ,  A61K38/28 ,  C07K14/575 ,  C07K7/06 ,  C07K7/02 ,  C07K7/64 ,  C07K11/00 ,  C07K14/47 ,  C07K14/785 ,  A61K39/00 ,  C07K14/005 ,  G01N33/574

CPC分类号： C07K14/705 ,  G01N33/574 ,  G01N33/57415 ,  G01N33/6872 ,  G01N2333/575 ,  G01N2800/2821 ,  G01N2800/52 ,  G01N2800/56

摘要： Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.

摘要翻译： 公开了用于确定条件进展，条件开始或治疗以患者脂肪细胞不平衡为特征的病症的功效的方法。 此外，公开了使用脂联素受体的某些C末端片段的单体，同二聚体和异二聚体形式治疗糖尿病，异常脂肪细胞活性和胰岛素抵抗的方法。 此外，治疗异常脂肪细胞活性，治疗代谢综合征，引起胰岛素分泌，增加胰岛素水平，抑制胰岛素降解酶，治疗阿尔茨海默病，治疗与脂联素水平相关的心血管疾病，抑制ADAM-17酶，抑制蛋白酶，治疗 公开了与TNF-α相关的病症和治疗与HER2-neu相关的病症。 还公开了组合物，剂型和试剂盒。

公开(公告)号：US20120135916A1

公开(公告)日：2012-05-31

申请号：US13265968

申请日：2010-04-13

申请人： Michael J. Pugia ,  Rui Ma

发明人： Michael J. Pugia ,  Rui Ma

IPC分类号： A61K38/16 ,  A61P25/28 ,  A61P9/00 ,  A61P31/18 ,  A61P11/00 ,  A61P19/00 ,  A61P37/00 ,  A61P17/00 ,  A61P9/10 ,  A61P17/06 ,  A61P37/06 ,  A61P19/02 ,  A61P29/00 ,  A61P19/10 ,  A61P1/00 ,  A61P1/04 ,  A61P25/00 ,  A61P19/04 ,  A61P11/06 ,  A61P35/00 ,  A61P5/48 ,  A61P3/00 ,  G01N33/566 ,  A61P3/10

CPC分类号： C07K14/705 ,  G01N33/574 ,  G01N33/57415 ,  G01N33/6872 ,  G01N2333/575 ,  G01N2800/2821 ,  G01N2800/52 ,  G01N2800/56

摘要： Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.

摘要翻译： 公开了用于确定条件进展，条件开始或治疗以患者脂肪细胞不平衡为特征的病症的功效的方法。 此外，公开了使用脂联素受体的某些C末端片段的单体，同二聚体和异二聚体形式治疗糖尿病，异常脂肪细胞活性和胰岛素抵抗的方法。 此外，治疗异常脂肪细胞活性，治疗代谢综合征，引起胰岛素分泌，增加胰岛素水平，抑制胰岛素降解酶，治疗阿尔茨海默病，治疗与脂联素水平相关的心血管疾病，抑制ADAM-17酶，抑制蛋白酶，治疗 公开了与TNF-α相关的病症和治疗与HER2-neu相关的病症。 还公开了组合物，剂型和试剂盒。

公开(公告)号：US20110301089A1

公开(公告)日：2011-12-08

申请号：US13211558

申请日：2011-08-17

申请人： Michael J. Pugia ,  Rui Ma

发明人： Michael J. Pugia ,  Rui Ma

IPC分类号： A61K38/17 ,  A61P9/00

CPC分类号： C07K14/72 ,  A61K38/00

摘要： Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.

摘要翻译： 公开了使用脂联素受体R1的C末端片段治疗糖尿病，异常脂肪细胞活性和胰岛素抵抗的方法。 还公开了使用脂联素受体R1的C末端片段在健康和糖尿病患者中分泌胰岛素的方法。 此外，公开了使用脂联素受体R1的C末端片段增加健康患者的胰岛素水平的方法。 另外，处理异常脂肪细胞活性，治疗代谢综合征，引起胰岛素分泌，增加胰岛素水平，抑制胰岛素降解酶，治疗阿尔茨海默氏病，治疗与脂联素水平相关的心血管疾病，抑制ADAM-17酶，治疗与 公开了TNF-α和治疗与HER2-neu相关的病症。 还公开了组合物，剂型和试剂盒。

公开(公告)号：US08017573B2

公开(公告)日：2011-09-13

申请号：US12169983

申请日：2008-07-09

申请人： Michael J. Pugia ,  Rui Ma

发明人： Michael J. Pugia ,  Rui Ma

IPC分类号： A61K38/17

CPC分类号： C07K14/72 ,  A61K38/00

摘要： Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.

摘要翻译： 公开了使用脂联素受体R1的C末端片段治疗糖尿病，异常脂肪细胞活性和胰岛素抵抗的方法。 还公开了使用脂联素受体R1的C末端片段在健康和糖尿病患者中分泌胰岛素的方法。 此外，公开了使用脂联素受体R1的C末端片段增加健康患者的胰岛素水平的方法。 另外，处理异常脂肪细胞活性，治疗代谢综合征，引起胰岛素分泌，增加胰岛素水平，抑制胰岛素降解酶，治疗阿尔茨海默氏病，治疗与脂联素水平相关的心血管疾病，抑制ADAM-17酶，治疗与 公开了TNF-α和治疗与HER2-neu相关的病症。 还公开了组合物，剂型和试剂盒。

公开(公告)号：US20130041236A1

公开(公告)日：2013-02-14

申请号：US13643633

申请日：2011-04-22

申请人： Michael J. Pugia ,  Gregory Paul Panebianco ,  Henry Lu

发明人： Michael J. Pugia ,  Gregory Paul Panebianco ,  Henry Lu

IPC分类号： A61B5/20 ,  G01N33/53 ,  G01N33/48 ,  B23P17/04

CPC分类号： A61B10/007 ,  A61B10/0045 ,  B01L3/5027 ,  B01L3/502707 ,  B01L3/508 ,  B01L2200/025 ,  B01L2200/027 ,  B01L2200/0621 ,  B01L2300/0654 ,  B01L2300/0816 ,  B01L2300/0832 ,  B01L2300/0851 ,  B01L2400/0406 ,  B01L2400/0457 ,  Y10T29/49826

摘要： A sample collection device having a sample container and microfluidic device having one or more microfluidic circuits, the system for analyzing biological samples. The microfluidic device has a sample inlet port, a microconduit in communication with the inlet port and with reaction chamber. The reaction chamber is connected to an air vent via another microconduit. Air may be vented from the microfluidic circuit via the air vent of the microfluidic circuit via an air vent in the sample container.

摘要翻译： 具有样品容器和具有一个或多个微流体电路的微流体装置的样品收集装置，用于分析生物样品的系统。 微流体装置具有样品入口，与入口连通的微型管道和反应室。 反应室通过另一个微型管道连接到通风口。 空气可以经由微流体回路的通气孔从微流体回路经由样品容器中的排气口排出。

公开(公告)号：US08304254B2

公开(公告)日：2012-11-06

申请号：US12598150

申请日：2008-03-14

申请人： Michael J. Pugia ,  James A. Profitt

发明人： Michael J. Pugia ,  James A. Profitt

IPC分类号： G01N1/38

CPC分类号： G01N35/1016 ,  G01N2035/1034 ,  Y10T436/144444 ,  Y10T436/25 ,  Y10T436/2575

摘要： Assays in which samples of biological fluids are dispensed onto reagent-containing porous substrates are improved in the accuracy and repeatability by dispensing the biological fluids in two or more fractions thereof, separated by intervals in which the biological fluid is not dispensed. Reagents and other fluids may be dispensed during the intervals when the biological fluid is not dispensed. Alternatively, reagents and other fluids may be dispensed in a similar manner onto substrates already containing biological fluids.

摘要翻译： 生物流体样品分配到含有试剂的多孔基材上的测定通过将生物流体分配在两个或更多个部分中，通过分配生物流体不分配的间隔而提高了精度和重复性。 在不分配生物流体的间隔期间，可以分配试剂和其它流体。 或者，可以以类似的方式将试剂和其它流体分配到已经含有生物流体的基底上。

公开(公告)号：US07858758B2

公开(公告)日：2010-12-28

申请号：US12144909

申请日：2008-06-24

申请人： Michael J. Pugia ,  Linda Anderson-Mauser ,  Solomon H. Murphy ,  Ronald G. Sommer ,  Shannon Gleason

发明人： Michael J. Pugia ,  Linda Anderson-Mauser ,  Solomon H. Murphy ,  Ronald G. Sommer ,  Shannon Gleason

IPC分类号： C07K16/00

CPC分类号： G01N33/573 ,  C07K16/18 ,  G01N2333/8107 ,  G01N2333/811 ,  G01N2333/976

摘要： Certain monoclonal antibodies are able to detect urinary trypsin inhibitors (UTIs) that are characteristic of disease in humans. In particular, the UTIs include AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2, as defined herein, also including the fragments and aggregates thereof.

摘要翻译： 某些单克隆抗体能检测出在人类中具有疾病特征的尿胰蛋白酶抑制剂（UTIs）。 特别地，UTI包括本文定义的AMBK，Bikunin，Uristatin，Uristatin-1，Uristatin-2，还包括其片段和聚集体。

公开(公告)号：US20100255592A1

公开(公告)日：2010-10-07

申请号：US12598150

申请日：2008-03-14

申请人： Michael J. Pugia ,  James A. Profitt

发明人： Michael J. Pugia ,  James A. Profitt

IPC分类号： G01N33/72 ,  G01N33/68 ,  G01N33/66

CPC分类号： G01N35/1016 ,  G01N2035/1034 ,  Y10T436/144444 ,  Y10T436/25 ,  Y10T436/2575

摘要： Assays in which samples of biological fluids are dispensed onto reagent-containing porous substrates are improved in the accuracy and repeatability by dispensing the biological fluids in two or more fractions thereof, separated by intervals in which the biological fluid is not dispensed. Reagents and other fluids may be dispensed during the intervals when the biological fluid is not dispensed. Alternatively, reagents and other fluids may be dispensed in a similar manner onto substrates already containing biological fluids.

摘要翻译： 生物流体样品分配到含有试剂的多孔基材上的测定通过将生物流体分配在两个或更多个部分中，通过分配生物流体不分配的间隔而提高了精度和重复性。 在不分配生物流体的间隔期间，可以分配试剂和其它流体。 或者，可以以类似的方式将试剂和其它流体分配到已经含有生物流体的基底上。

公开(公告)号：US20100172801A1

公开(公告)日：2010-07-08

申请号：US12688346

申请日：2010-01-15

申请人： Michael J. Pugia ,  James A. Profitt ,  Hai-Hang Kuo ,  Gert Blankenstein ,  Ralf-Peter Peters ,  Lloyd S. Schulman

发明人： Michael J. Pugia ,  James A. Profitt ,  Hai-Hang Kuo ,  Gert Blankenstein ,  Ralf-Peter Peters ,  Lloyd S. Schulman

IPC分类号： G01N30/00 ,  G01N33/487

CPC分类号： B01L3/502746 ,  B01L3/502723 ,  B01L2200/0684 ,  B01L2200/16 ,  B01L2300/0816 ,  B01L2400/0406 ,  B01L2400/0409 ,  B01L2400/0418 ,  B01L2400/0487 ,  B01L2400/0688 ,  B01L2400/086 ,  Y10T436/2575

摘要： Analytical results obtained with microfluidic devices are improved by providing structural features in areas containing dry supported reagents, the structural features directing the flow of a sample over the area in a predetermined uniform manner and facilitating the purging of air.

摘要翻译： 通过在含有干支持试剂的区域中提供结构特征来改进用微流体装置获得的分析结果，其结构特征以预定均匀的方式引导样品流过该区域并促进空气吹扫。